What can be expected from the Molecular Diagnostics market? Which areas are going to grow at the fastest rates? This Visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.
Our 223-page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2015-2025 and other analyses show you commercial prospects
Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
See revenue forecasts for the leading submarkets and indications
How will submarkets perform to 2025? Our study forecasts revenues in the following Molecular Diagnostics (MDx) submarkets:
• Infectious disease testing
• Oncology Testing
• Blood screening
• Genetic testing
• Tissue Typing (HLA)
See revenue forecasts for the leading international markets
How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:
• US
• Japan
• Germany
• France
• Italy
• Spain
• UK
• China
• Brazil
• Russia
• India
• South Korea
• Mexico
Leading companies and potential for market growth
Overall revenue for the Molecular Diagnostics (MDx) market will reach $10.45bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. An ageing population and increasing incidence of chronic diseases, especially cancer, globally will drive sales to 2025.
Our work analyses the key companies in the market. See Visiongain’s analysis of 7 leading companies, including these:
• Roche Diagnostics
• Qiagen
• Hologic
• Becton, Dickinson & Company
• bioMérieux
• Cepheid
• Agilent Technologies
A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Analysis of assays and instruments currently on the market as well as pipeline products
• Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect Molecular Diagnostics industry?
Our new report discusses issues and events affecting the Molecular Diagnostics market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of national markets
• Unclear regulatory landscape challenging new entrants and major market players alike
• Emerging technologies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How The Molecular Diagnostics (MDx) Market Forecast 2015-2025 report helps you
In summary, our 223-page report gives you the following knowledge:
• Revenue forecasts to 2025 for the Molecular Diagnostics (MDx) market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2025 for submarkets in each – discover prospects for leading assays and instrumentation in the following areas: Infectious Disease testing including Chlamydia Trachonomatis (CT), Neisseriae Gonnohroea (NG), Human Papillomavirus (HPV), HIV, Healthcare associated infections (MRSA & Clostridium Difficile) Hepatitis C (HCV) and Respiratory infections (including Influenza and RSV), Oncology Testing and companion diagnostics, Blood Screening, Genetic Testing (including Cystic Fibrosis testing, Thrombophilia testing, inflammatory disease testing and rare disease testing) and Tissue (HLA) typing.
• Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5, BRIC South Korea and Mexico
• Assessment of 7 leading companies – analysis of Molecular Diagnostic products, revenue, mergers & acquisitions, sales by region and upcoming product releases
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the Molecular Diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 The Molecular Diagnostics Market Overview
1.2 Molecular Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Molecular Diagnostics
2.1 What are In Vitro Diagnostic (IVD) Tests?
2.2 Classifying In Vitro Diagnostics
2.2.1 FDA Classifications
2.2.2 The EC (European Commission) Classification
2.2.3 IVD Classification in Australia
2.3 IVD Submarkets
2.3.1 Clinical Chemistry
2.3.2 Immunochemistry
2.3.3 Point-of-care Testing (Including Self-Monitoring Blood Glucose Tests)
2.3.4 Molecular Diagnostics
2.3.4.1 Infectious Disease Testing
2.3.4.2 Oncology Testing
2.3.4.3 Blood Screening
2.3.4.4 Genetic Testing
2.3.4.5 Tissue Typing (HLA Testing)
2.3.5 Clinical Microbiology
2.3.6 Haematology/ Haemostasis
2.4 Regulation of the IVD and MDx Market
2.4.1 FDA and CLIA Regulation of IVD and MDx Tests
2.4.2 Regulation of IVD/MDx Tests in the EU: The EC (European Commission) Classification
2.4.3 Top Ten Challenges in Regulation for In-Vitro Diagnostics
2.4.3.1 Challenges in Regulations of MDx Tests
2.5 Device Excise Tax: A Threat to the Diagnostics Manufacturers
3. The Molecular Diagnostics Segment within the In Vitro Diagnostics Market, 2015-2025
3.1 Molecular Diagnostics in the IVD Market, 2014
3.2 Sales Forecast for the Global IVD Market 2015-2025
3.3 Molecular Diagnostics Gaining A Greater Share of the IVD Market
4. The Molecular Diagnostics Market by Sectors, 2015-2025
4.1 The Molecular Diagnostic Market by Sectors, 2014
4.2 The Molecular Diagnostic Market by Sectors 2015-2025
4.2.1 Market Shares of the Molecular Diagnostics Sectors 2015-2025
4.3 The Infectious Disease Testing Market 2015-2025
4.3.1 Breakdown of the MDx Infectious Disease Testing Market by Disease, 2014
4.3.1.1 CT/NG
4.3.1.2 HPV Testing
4.3.1.3 HIV
4.3.1.4 Healthcare Associated Infections (HAI)
4.3.1.5 Hepatitis C (HCV)
4.3.1.6 Respiratory Infections
4.4 The Oncology Testing Market, 2015-2025
4.4.1 Targeted Therapies: A Major Driver of the Oncology Testing Market
4.4.2 Molecular Diagnostics: Currently Concentrated on a Few Cancer Indications
4.4.2.1 Breast Cancer
4.4.2.2 Prostate Cancer
4.4.2.2.1 Prostate Cancer Pipeline Biomarkers
4.4.2.2.1.1 TMPRSS2-ERG (OriGene)
4.4.2.2.1.2 PTEN
4.4.2.3 Colorectal Cancer
4.5 The Blood Screening Market 2015-2025
4.5.1 Grifols’ Acquisition of Novartis’s Blood Screening Unit
4.5.2 Leading Blood Screening Test Products
4.5.2.1 Cobas s 201 System (Roche Molecular)
4.5.2.2 Procleix Assays (Grifols)
4.6 The Genetic Testing Market 2015-2025
4.6.1 Genetic Testing by Clinical Impact Area
4.6.2 Genetic Testing: Potential beyond Oncology
4.6.3 Cystic Fibrosis
4.6.4 Factor V Leiden and Factor II Thrombophilia
4.6.5 Inflammatory Diseases
4.6.5.1 Alzheimer’s Disease (AD)
4.6.5.2 Rheumatoid Arthritis
4.6.5.2.1 Vectra®DA (Crescendo Bioscience)
4.6.5.2.2 Quest Diagnostics: Biomarker Study
4.6.5.3 Rare Diseases
4.7 The Tissue Typing (HLA Typing) Market 2015-2025
4.7.1 Tissue Typing: Next-Generation Sequencing
5. The Leading Molecular Diagnostics National Markets, 2015-2025
5.1 Regional Breakdown of the Global MDx Market, 2014
5.2 The Global MDx Market Forecast, 2015-2025
5.3 The Regional Market Shares of the MDx Market, 2014, 2019 and 2025
5.4 The US MDx Market 2014
5.4.1 The US MDx Market Forecast 2015-2025
5.4.1.1 United States: Diagnostic Reimbursement
5.5 The European MDx Markets Forecast 2015-2025
5.5.1 Changes in the Shares of the Leading European Markets, 2014, 2019 and 2025
5.5.2 Shares of the Major European Markets in a Global Context
5.5.3 The German MDx Market Forecast 2015-2025
5.5.3The French MDx Market Forecast 2015-2025
5.5.4 The Italian MDx Market Forecast 2015-2025
5.5.5 The Spanish MDx Market Forecast 2015-2025
5.5.6 The UK MDx Market Forecast 2015-2025
5.5.7 The Other European MDx Markets Forecast 2015-2025
5.6 The Japanese MDx Market Forecast 2015-2025
5.7 The Chinese MDx Market Forecast 2015-2025
5.7.1 China: Increasing Cancer Burden
5.8 The Brazilian MDx Market Forecast 2015-2025
5.9 The Russian MDx Market Forecast 2015-2025
5.10 The Indian MDx Market Forecast 2015-2025
5.10.1 India: Expansion of Healthcare Provisions
5.11 The South Korean MDx Market Forecast 2015-2025
5.12 The Mexican MDx Market Forecast 2015-2025
5.13 The Rest of the World Market Forecast 2015-2025
6. The Leading Companies in the Molecular Diagnostics Market, 2015
6.1 Roche Diagnostics
6.1.1 Roche: Global Presence
6.1.2 Roche Diagnostics, 2015-2025
6.1.3 Roche Diagnostics Business Performance within the IVD Market, 2014
6.1.3.1 Molecular Diagnostics Sales Performance, 2014
6.1.3.2 Molecular Diagnostic Sales by Region, 2014
6.1.4 Roche Diagnostics: MDx Product Launches and Indication Expansion, 2015
6.1.4.1 Roche Diagnostics: Product Launch Plans, 2015
6.1.5 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Market Leader
6.1.5.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
6.1.5.2 IQuum Acquisition Allows Movement into POC MDx Market
6.1.5.3 Seragon Acquisition Strengthens Leading Position in Oncology
6.1.5.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
6.1.5.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
6.1.5.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
6.1.5.7 Ariosa Acquisition Adds NIPT to MDx Portfolio
6.1.5.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
6.1.5.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
6.1.5.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the MDx Market Leader
6.2 Qiagen NV
6.2.1 Sales and Recent Performance Analysis, 2014
6.2.2 Qiagen Sales by Region, 2014
6.2.3 Qiagen Sales by Segment, 2014
6.2.4 Qiagen: Molecular Diagnostics
6.2.5 Molecular Diagnostics: Product Expansion
6.2.5.1 QIASymphony
6.2.5.2 QuantiFERON-TB Gold: Expansion into Asia
6.2.5.3 Personalised Healthcare: Collaborative Efforts
6.2.5.4 Qiagen’s Software Company Acquisitions Cement Leadership in Bioinformatics
6.3 Hologic
6.3.1 Hologic Recent Sales Performance by Business Segment, 2014
6.3.2 Hologic Molecular Diagnostics: Product Portfolio
6.4 Becton, Dickinson and Company
6.4.1 Sales and Financial Performance, 2014
6.4.2 Sales and Financial Performance by Region, 2014
6.4.3 Becton, Dickinson and Company Diagnostics Sales and Financial Performance, 2013-2014
6.4.4 BD Diagnostics: Product Portfolio
6.4.5 BD Diagnostics: Mergers and Acquisitions
6.5 bioMérieux
6.5.1 Sales and Recent Performance Analysis, 2010-2014
6.5.2 Sales by Region, 2014
6.5.3 Sales by Technology, 2014
6.5.4 Molecular Diagnostics: Product Portfolio
6.5.5 Companion Diagnostics: Collaborations with GSK and Novartis
6.5.6 Mergers, Acquisitions and Collaborations
6.5.7 bioTheranostics: Subsidiary for Oncology Diagnostics
6.6 Cepheid
6.6.1 Sales and Recent Performance Analysis, 2010-2014
6.6.2 Sales by Industry Segment, 2013-2014
6.6.3 Sales by Region, 2012-2014
6.6.4 Cepheid: Product Line
6.6.5 Cepheid: Business strategy
6.7 Agilent Technologies
6.7.1 Sales and Recent Performance Analysis, 2014
6.7.2 Sales Performance by Business Segment, 2014
6.7.3 Agilent Technologies: Strong Player in Target Enrichment for Next-Generation Sequencing
7. Qualitative Analysis of the MDx Market, 2015-2025
7.1 MDx Market: Drivers and Restraints
7.2 SWOT Analysis of the MDx Market, 2015-2025
7.2.1 Strengths
7.2.1.1 Patient Demographics
7.2.1.2 Increased Awareness
7.2.1.3 High Growth in Oncology Molecular Diagnostics
7.2.1.4 Increasing Laboratory Test Menus
7.2.1.5 Personalised Medicine: Optimising Treatment Outcomes
7.2.2 Weaknesses
7.2.2.1 Lack of Clear Regulatory Guidelines for Molecular Diagnostics
7.2.2.2 Reimbursement Challenges for Molecular Diagnostic Companies
7.2.2.3 Consolidation of Healthcare Systems Increases Pricing Pressure
7.2.2.4 MDx: An Expensive, but Undervalued Diagnostic Tool
7.2.3 Opportunities
7.2.3.1 Next-Generation Sequencing
7.2.3.2 Emerging Markets
7.2.3.3 The Emergence of New Microorganisms
7.2.4 Threats
7.2.4.1 US Medical Device Excise Tax
7.2.4.2 Gene Patents: Controversial Ruling
7.3 Porter’s Five Forces Analysis of the MDx Market
7.3.1 Rivalry among Competitors [High]
7.3.2 Threat of New Entrants [Medium]
7.3.3 Power of Suppliers [Medium]
7.3.4 Power of Buyers [High]
7.3.5 Threat of Substitutes [High]
8. Research Interview
8.1 Kai te Kaat, Vice President, Global Product Management Life Sciences, Head of NGS Program, QIAGEN NV
8.1.1 QIAGEN: Pioneers in NGS Technology
8.1.2 The Future of NGS Outside Oncology
8.1.3 QIAGEN: Leading Progress in Bioinformatics
8.1.4 Regional Demand for NGS and NGS in the Wider Diagnostics Market
9. Conclusion
9.1 The Molecular Diagnostics Market: Growing Market Share
9.2 Molecular Diagnostics: Oncology Testing Market Growth
9.3 Commercial Drivers of the Molecular Diagnostics Market
9.4 Commercial Restraints of the Molecular Diagnostics Market
9.5 Emerging Markets
9.6 Concluding Remarks
10. Glossary
List of Tables
Table 1.1 Molecular Diagnostics Leading National Markets Forecast: Revenues ($bn), AGR (%) and CAGR (%), 2014-2025
Table 2.1 Advantages and Disadvantages of POC Diagnostics, 2015
Table 3.1 World IVD Market: Revenues ($bn) and Market Share (%) by Segment, 2014
Table 3.2 World IVD Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2014-2025
Table 3.3 Market Shares (%) of MDx in the IVD Market, 2014, 2019 & 2025
Table 4.1 The MDx Market: Revenues ($bn) and Market Shares (%) by Segment, 2014
Table 4.2 The Global MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Segment, 2014-2025
Table 4.3 The MDx Market: Market Shares (%) by Segment, 2014, 2019 and 2025
Table 4.4 The Infectious Disease Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.5 The Infectious Disease Testing Market: Revenues ($bn) and Market Share (%) by Disease, 2014
Table 4.6 Selected FDA and CE-Approved Molecular Diagnostics Test for CT/NG, 2015
Table 4.7 Selected FDA and CE-Approved Molecular Diagnostics Test for HPV, 2015
Table 4.8 Selected FDA and CE-Approved Molecular Diagnostics Tests for HIV, 2015
Table 4.9 Selected FDA and CE-Approved Molecular Diagnostics Test for HAIs, 2015
Table 4.10 Selected FDA and CE-Approved Molecular Diagnostics Tests for HCV, 2015
Table 4.11 Selected FDA-Approved Molecular Diagnostics Test for Respiratory Infections, 2015
Table 4.12 The Oncology Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.13 Examples of Clinically Relevant Cancer Biomarkers Tied with a Drug, 2015
Table 4.14 Selected List of FDA-Approved MDx Tests for Breast Cancer, 2015
Table 4.15 Selected List of FDA-Approved MDx Tests for Prostate Cancer, 2015
Table 4.16 Selected List of FDA-Approved MDx tests for Colorectal Cancer, 2015
Table 4.17 The Blood Screening Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.18 The Genetic Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.19 Selected Genetic Tests for Cystic Fibrosis on the Market, 2015
Table 4.20 Selected Genetic Tests for Factor V Leiden/Factor II Thrombophilia on the Market, 2015
Table 4.21 Selected Alzheimer’s MDx Diagnostic Tests in Development, 2015
Table 4.22 The Tissue Typing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.23 Selected tissue typing Kits on the Market, 2015
Table 5.1 The MDx Market: Revenue ($bn) and Market Share (%) by Region, 2014
Table 5.2 The MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2014-2025
Table 5.3 The MDx Market: Market Shares (%) by Regional Markets, 2014, 2019 and 2025
Table 5.4 The US MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.5 The European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.6 The European MDx Market: Market Shares (%) by Country, 2014, 2019 and 2025
Table 5.7 The German MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.8 The French MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.9 The Italian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.10 The Spanish MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.11 The UK MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.12 The Other European MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.13 The Japanese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.14 The Chinese MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.15 The Brazilian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.16 The Russian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.17 The Indian MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.18 The South Korean MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.19 The Mexican MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 5.20 The Rest of the World MDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 6.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014
Table 6.2 Roche Molecular Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2014
Table 6.3 Roche Diagnostics: Key Product Launches (Instruments/Devices) Planned for 2015
Table 6.4 Roche Diagnostics: Key Product Launches (Tests/Assays) Planned for 2015
Table 6.5 Qiagen: Revenue ($m) and Revenue Share (%) by Region, 2012-2014
Table 6.6 Hologic: Revenue ($bn) and Revenue Share (%) by Segment, 2012-2014
Table 6.7 Hologic: Diagnostics Revenue ($bn) and Revenue Share (%) by Segment, 2014
Table 6.8 Becton, Dickinson and Company: Revenue ($bn) and AGR (%) by Region, 2012-2014
Table 6.9 Becton, Dickinson and Company: Sales ($bn), AGR (%) by Diagnostics Division, 2013-2014
Table 6.10 bioMérieux : Revenue ($bn) and AGR (%), 2010-2014
Table 6.11 bioMérieux: Revenue ($m) and Revenue Change (%) by Region, 2013-2014
Table 6.12 bioMérieux: Revenue ($bn) and Revenue Share (%) by Region, 2014
Table 6.13 bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2013-2014
Table 6.14 Cepheid: Revenue ($m) and Net Income ($m), 2010-2014
Table 6.15 Cepheid: Revenue ($m) and AGR (%) by Industry, 2012-2014
Table 6.16 Cepheid: Revenue ($m), AGR (%) and CAGR (%) by Region and Industry, 2012-2014
Table 6.17 Agilent Technologies: Revenue ($bn) and AGR (%), 2010-2014
Table 6.18 Agilent Technologies: Revenue ($bn) and AGR (%) by Business Segment, 2010-2014
Table 6.19 Agilent Technologies Life Sciences and Diagnostics: Revenue ($bn) by Segment, 2012-2014
Table 7.1 SWOT Analysis of the Global MDx Market, 2015-2025
Table 9.1 MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2014, 2019 and 2025
List of Figures
Figure 1.1 Molecular Diagnostics: Overview of Submarkets
Figure 3.1 World IVD Market: Revenues ($bn) by Segment, 2014
Figure 3.2 World IVD Market: Revenue Shares (%) by Segment, 2014
Figure 3.3 World IVD Market Forecast: Revenue ($bn) and AGR (%) by Segment, 2014-2025
Figure 3.4 World MDx Market Share (%) in the IVD Market, 2019
Figure 3.5 World MDx Market Share (%) in the IVD Market, 2025
Figure 4.1 The MDx Market Shares (%) by Sector in the IVD Market, 2014
Figure 4.2 The MDx Market: Revenue ($bn) by Segment, 2014
Figure 4.3 The MDx Market: Market Shares (%) by Segment, 2014
Figure 4.4 The Global MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.5 The MDx Market: Market Shares (%) by Segment, 2019
Figure 4.6 The MDx Market: Market Shares (%) by Segment, 2025
Figure 4.7 The Infectious Disease Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.8 The Infectious Disease Testing Market: Market Shares (%) by Disease, 2014
Figure 4.9 The Oncology Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.10 The Cancer Treatment Sequence and the Application of Molecular Diagnostics and Companion Diagnostics
Figure 4.11 The Blood Screening Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.12 The Genetic Testing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 4.13 The Genetic Testing Market by Clinical Impact Area, 2014
Figure 4.14 The Tissue Typing Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.1 The MDx Market: Market Shares (%) by Region, 2014
Figure 5.2 The MDx Market: Revenue ($bn) by Region, 2014
Figure 5.3 The MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.4 The MDx Market: Market Shares (%) by Region, 2019
Figure 5.5 The MDx Market: Market Shares (%) by Region, 2025
Figure 5.6 The US MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.7 The European MDx Market Forecast: Revenue ($bn) by Region, AGR (%), 2014-2025
Figure 5.8 The European MDx Market: Market Shares (%) by Country, 2014
Figure 5.9 The European MDx Market: Market Shares (%) by Country, 2019
Figure 5.10 The European MDx Market: Market Shares (%) by Country, 2025
Figure 5.11 Europe in The Global MDx Market: Market Shares (%) by Country, 2014
Figure 5.12 Europe in The Global MDx Market: Market Shares (%) by Country, 2019
Figure 5.13 Europe in The Global MDx Market: Market Shares (%) by Country, 2025
Figure 5.14 The German MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.15 The French MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.16 The Italian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.17 The Spanish MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.18 The UK MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.19 The Other European MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.20 The Japanese MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.21 The Chinese MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.22 The Brazilian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.23 The Russian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.24 The Indian MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.25 The South Korean MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.26 The Mexican MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 5.27 The Rest of the World MDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2025
Figure 6.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2014
Figure 6.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2014
Figure 6.3 Roche Molecular Diagnostics: Revenue Share (%) by Region, 2014
Figure 6.4 Qiagen:Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2010-2014
Figure 6.5 Qiagen: Revenue ($m) by Region, 2014
Figure 6.6 Qiagen: Revenue Share (%) by Region, 2014
Figure 6.7 Hologic: Revenue ($bn) by Business Segment, 2012-2014
Figure 6.8 Hologic: Revenue Share (%) by Business Segment, 2014
Figure 6.9 Hologic: Diagnostics Revenue Share (%) by Business Segment, 2014
Figure 6.10 Becton, Dickinson and Company: Revenue Share (%) by Segment, 2014
Figure 6.11 Becton, Dickinson and Company: Revenue ($bn) by Region, 2012-2014
Figure 6.12 Becton, Dickinson and Company: Revenue Share (%) by Region, 2014
Figure 6.13 Becton, Dickinson and Company: Revenue Share (%) by Diagnostics Division, 2014
Figure 6.14 bioMérieux: Revenue ($m) and AGR (%), 2010-2014
Figure 6.15 bioMérieux: Revenue ($bn) by Region, 2014
Figure 6.16 bioMérieux: Revenue Share (%) by Region, 2014
Figure 6.17 bioMérieux: Revenue Share (%) by Technology, 2014
Figure 6.18 Cepheid: Revenue ($m) and Net Income ($m), 2010-2014
Figure 6.19 Cepheid: Revenue Share (%) by Industry, 2014
Figure 6.20 Cepheid: Revenue Share (%) by Region, 2012
Figure 6.21 Cepheid: Revenue Share (%) by Region, 2014
Figure 6.22 Agilent Technologies: Revenue ($bn) and AGR (%), 2010-2014
Figure 6.23 Agilent Technologies: Revenue Share (%) by Business Segment, 2014
Figure 6.24 Agilent Technologies Life Sciences and Diagnostics: Revenue Share (%) by Segment, 2014
Figure 7.1 MDx Market: Drivers and Restraints, 2015-2025
Figure 7.2 The Global Over 65 Population: Forecast (millions, AGR%), 2014-2025
Figure 7.3 Porter’s Five Forces Analysis of the MDx Market, 2015-2025
Figure 9.1 MDx and Other In Vitro Diagnostics: World Revenue ($bn) Forecast, 2014, 2019 and 2025
Figure 9.2 Molecular Diagnostics Market Forecast: AGRs (%) in the US, India, China and Global Market, 2014-2025
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
